| DHR |
Report |
Core revenue growth |
BEAT |
pred ~2.4% vs. cons 2.0% |
MEDIUM |
| DHR |
Report |
Adjusted diluted EPS |
BEAT |
pred ~$1.89 vs. cons $1.84 |
HIGH |
| DHR |
Report |
Adjusted operating margin |
BEAT |
pred ~27.0% vs. cons 26.6% |
MEDIUM |
| DHR |
Guide |
Adjusted diluted EPS guidance |
BETTER |
guide ~$8.48 midpoint ($8.40-$8.55) vs. cons $8.47 (FY2026) |
MEDIUM |
| DHR |
Guide |
Core revenue growth guidance |
UNCHANGED |
guide ~3%-6% vs. cons 3.4% (FY2026) |
HIGH |
| DHR |
Guide |
Core revenue growth guidance |
UNCHANGED |
guide ~4.0% vs. cons 4.0% (2026Q3) |
MEDIUM |
| DHR |
Guide |
Adjusted operating margin guidance |
UNCHANGED |
guide ~26.0% vs. cons 26.1% (2026Q3) |
MEDIUM |
| DHR |
Return |
Day-1 residual (stock − beta × S&P 500) |
+3.1% |
— |
MEDIUM |
| DHR |
Return |
5-day cumulative residual |
+4.2% (FOLLOW-THROUGH) |
Modest FY2026 EPS revisions and de-risked second-half core-growth math should extend the initial reaction; sustained bioprocessing equipment orders and improving Life Sciences bookings would lift 2027 estimates rather than reveal an implicit out-period cut. |
MEDIUM |